{"id":427,"date":"2024-01-30T11:03:40","date_gmt":"2024-01-30T15:03:40","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=427"},"modified":"2024-01-30T11:03:40","modified_gmt":"2024-01-30T15:03:40","slug":"senator-reiterates-ftc-warnings-regarding-inhaler-patents-in-orange-book","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2024\/01\/30\/senator-reiterates-ftc-warnings-regarding-inhaler-patents-in-orange-book\/","title":{"rendered":"Senator reiterates FTC warnings regarding inhaler patents in Orange Book"},"content":{"rendered":"<p>Senator Tammy Baldwin (D-WI) <a href=\"https:\/\/www.baldwin.senate.gov\/news\/press-releases\/senator-baldwin-demands-big-pharma-stop-unfair-practices-that-reduce-competition-raise-prices-for-inhalers\">sent letters<\/a> this week to companies warning of improper Orange Book listings of patents for inhalers, following up on the <a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2023\/11\/08\/ftc-issues-notice-letters-regarding-orange-book-listings\/\">FTC&#8217;s focus<\/a> on potential anticompetitive harm of improper listings. According to Senator Baldwin\u2019s letters, the recipients of the letters were warned by the FTC in November regarding the listing of inhaler patents, but have not removed the patents from the Orange Book. The letters follow an <a href=\"https:\/\/www.baldwin.senate.gov\/news\/press-releases\/senators-baldwin-colleagues-launch-investigation-into-pharmaceutical-companies-high-price-of-asthma-inhalers\">investigation<\/a> launched earlier this month by the Senate Committee on Health, Education, Labor, and Pensions (of which Senator Baldwin is a member) into the prices of inhalers.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Senator Tammy Baldwin (D-WI) sent letters this week to companies warning of improper Orange Book listings of patents for inhalers, following up on the FTC&#8217;s focus on potential anticompetitive harm of improper listings. According to Senator Baldwin\u2019s letters, the recipients of the letters were warned by the FTC in November regarding the listing of inhaler &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2024\/01\/30\/senator-reiterates-ftc-warnings-regarding-inhaler-patents-in-orange-book\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Senator reiterates FTC warnings regarding inhaler patents in Orange Book&#8221;<\/span><\/a><\/p>\n","protected":false},"author":659,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[380,421,96,274,50],"ppma_author":[668,667],"class_list":["post-427","post","type-post","status-publish","format-standard","hentry","category-general","tag-antitrust","tag-ftc","tag-orange-book","tag-patents","tag-pharma"],"authors":[{"term_id":668,"user_id":659,"is_guest":0,"slug":"sckulik","display_name":"Sarah O'Laughlin Kulik","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2023\/09\/kuliksaraholaughlin-100x100.jpg","author_category":"","last_name":"Kulik","first_name":"Sarah","job_title":"","user_url":"https:\/\/www.duanemorris.com\/attorneys\/saraholaughlinkulik.html","description":"<A HREF=\"https:\/\/www.duanemorris.com\/attorneys\/saraholaughlinkulik.html\">Read Sarah's Bio<\/a>"},{"term_id":667,"user_id":660,"is_guest":0,"slug":"spmcconnell","display_name":"Sean P. McConnell","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2023\/09\/mcconnellsean-100x100.jpg","author_category":"","last_name":"McConnell","first_name":"Sean","job_title":"","user_url":"https:\/\/www.duanemorris.com\/attorneys\/seanpmcconnell.html","description":"<A HREF=\"https:\/\/www.duanemorris.com\/attorneys\/seanpmcconnell.html\">Read Sean's Bio<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/659"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=427"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/427\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=427"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}